Date: January 28, 2024
Reason for Alert: Administration of Arexvy, the GSK RSV vaccine that is not FDA approved for pregnant persons, has been reported.

Potential risks of the stated issue: Patient safety due to lack of pregnancy indication and potential lack
of prevention of RSV in newborns.

Recommendations for practice:

• Pfizer RSV Vaccine (Absryvo) is the only recommended RSV vaccine for pregnant patients from 32 through 36 weeks” gestation.
• Include “Pregnancy Indication-Pfizer RSV vaccine (Abrysvo) only” on prescriptions for pharmacies.
• Locate pharmacies that administer the Pfizer RSV vaccination (Abrysvo) at the nearest location to
• the pregnant patient by using the following location finder resource: pfizervax.com D. Meaney-Delman (personal communication, December 19, 2023)
• The shelf life for Pfizer Abrysvo is 24 months with storage at standard refrigerator temperatures between 2-8 C. This means that some vaccines can be stored and used next year, thus reducing the risk of wasting vaccines.

Benefits of recommendations: Increase patient safety and protection of RSV in pregnant patients and
newborns.

References: Center for Disease Control and Prevention (2024). National Center for Immunization and
Respiratory Diseases (NCIRD), Division of Viral Diseases The National Respiratory and Enteric Virus
Surveillance System (NREVSS): RSV National Trends. https://www.cdc.gov/surveillance/nrevss/rsv/natltrend.html

RSV Vaccine Practice Alert 1/2024